Skip to Main Content

Author Details

Roberta Ferraldeschi
Astex Pharmaceuticals
2004
61
34
PMIDPaper TitleJournal TitlePublished Year
34330842ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.Mol Cancer Ther2021
34474469Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.Blood Adv2021
32616501First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.Clin Cancer Res2020
31900279A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.Clin Cancer Res2020
31113841Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.Clin Cancer Res2019
30581389Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy.Front Pharmacol2018
29911685Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.Eur Urol Oncol2018
27539393Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.BJU Int2017
28751446Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.Clin Cancer Res2017
26965561Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.Eur Urol2016
27197266Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Cancer Res2016
27444228Drug discovery in advanced prostate cancer: translating biology into therapy.Nat Rev Drug Discov2016
27246360Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Clin Genitourin Cancer2016
27245279Clinical development of new drug-radiotherapy combinations.Nat Rev Clin Oncol2016
24837363Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.Oncogene2015
28843286Integrative Clinical Genomics of Advanced Prostate Cancer.Cell2015
26510020DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med2015
26379078PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.Br J Cancer2015
26537258Plasma AR and abiraterone-resistant prostate cancer.Sci Transl Med2015
26219697Maximizing the Therapeutic Potential of HSP90 Inhibitors.Mol Cancer Res2015
26085511Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.Clin Cancer Res2015
26000489Integrative clinical genomics of advanced prostate cancer.Cell2015
25719830Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.Br J Cancer2015
25454616PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Eur Urol2015
25538172Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.Ann Oncol2015
25563847Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Nat Rev Urol2015
24060820CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Clin Pharmacol Ther2014
25232177Tumor clone dynamics in lethal prostate cancer.Sci Transl Med2014
25314055Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.Br J Cancer2014
24840076Evolution of androgen receptor targeted therapy for advanced prostate cancer.Nat Rev Clin Oncol2014
24685433External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.Eur Urol2014
24300975Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.Br J Cancer2014
24295792Visceral disease in castration-resistant prostate cancer.Eur Urol2014
24433842Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer.Eur J Cancer2014
24411987Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.Eur Urol2014
24074764Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.Eur J Cancer2014
23020876Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.Annu Rev Med2013
24169353First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Br J Cancer2013
23928659Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.Br J Cancer2013
23470964Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.Clin Cancer Res2013
23204221Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer.Clin Chem2013
23313031Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.Eur Urol2013
23337755Agents that target androgen synthesis in castration-resistant prostate cancer.Cancer J2013
21986558Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.Mol Cell Endocrinol2012
22310961Lack of caveolin-1 (P132L) somatic mutations in breast cancer.Breast Cancer Res Treat2012
22418701Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients.Breast Cancer Res Treat2012
20809362Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.Breast Cancer Res Treat2011
21733927Pharmacogenetics and pharmacogenomics: a clinical reality.Ann Clin Biochem2011
21422424Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer.J Clin Oncol2011
20823421Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.J Clin Oncol2010
  • 1 - 50 of 61

Recommended Authors

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 8
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 3
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 15
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 11
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 17
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 1
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 15
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 30
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 6
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 7
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 42
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 44
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 27
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 37
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 37
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 8
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 22
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 19
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 22
Michael A Carducci
Johns Hopkins School of Medicine
Career Start Year 1995
Number of shared co-authors 27
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Career Start Year 1994
Number of shared co-authors 17
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 16
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 19
Urban Emmenegger
Odette Cancer Centre
Career Start Year 1991
Number of shared co-authors 7
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 28
Martin E Gleave
University of British Columbia
Career Start Year 1987
Number of shared co-authors 50
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1987
Number of shared co-authors 35
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 41
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 30
Ronald de Wit
Erasmus MC Cancer Institute
Career Start Year 1972
Number of shared co-authors 18

Collaborators

Johann S de Bono
The Institute for Cancer Research
Co-authored papers 35
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 28
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 15
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Co-authored papers 14
Susana Miranda
The Institute of Cancer Research
Co-authored papers 13
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 12
Penny Flohr
The Institute of Cancer Research
Co-authored papers 10
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 9
Suzanne Carreira
The Institute of Cancer Research
Co-authored papers 6
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 4
Paul Workman
The Institute of Cancer Research
Co-authored papers 4
Lakshmi P Kunju
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 4
Francesca Demichelis
University of Trento
Co-authored papers 4
Yi-Mi Wu
University of Michigan Medical School ann arbor
Co-authored papers 4
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 3
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Fiona Blackhall
The University of Manchester
Co-authored papers 3
Dana E Rathkopf
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 3
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 3
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 3
Mark A Rubin
University of Bern
Co-authored papers 3
Xuhong Cao
Michigan Center for Translational Pathology.
Co-authored papers 3
Wei Yuan
The Institute for Cancer Research
Co-authored papers 3
Stephen R Plymate
University of Washington
Co-authored papers 3
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Co-authored papers 2
Manaswi Gupta
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 2
Rosina T Lis
National Cancer Institute
Co-authored papers 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Pankaj Vats
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 2
Release 1.2